Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Marcela V Maus"'
Publikováno v:
Med. 3:538-564
Since their approval 5 years ago, chimeric antigen receptor (CAR) T cells have gained great importance in the daily clinical practice and treatment of hematological malignancies, although many challenges to their use remain, such as limited long-term
Autor:
Zachariah DeFilipp, Marcela V. Maus
Publikováno v:
Nature Medicine. 29:785-786
Autor:
Stefanie R. Bailey, Sonika Vatsa, Rebecca C. Larson, Amanda A. Bouffard, Irene Scarfò, Michael C. Kann, Trisha R. Berger, Mark B. Leick, Marc Wehrli, Andrea Schmidts, Harrison Silva, Kevin A. Lindell, Ashley Demato, Kathleen M.E. Gallagher, Matthew J. Frigault, Marcela V. Maus
Publikováno v:
Blood Cancer Discov
Chimeric antigen receptor (CAR) T cells induce impressive responses in patients with hematologic malignancies but can also trigger cytokine release syndrome (CRS), a systemic toxicity caused by activated CAR T cells and innate immune cells. Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8be6f624ee9c65eed1694036ba23d9
https://europepmc.org/articles/PMC9414118/
https://europepmc.org/articles/PMC9414118/
Publikováno v:
Annual Review of Medicine. 72:365-382
Adoptive transfer of T cells modified with chimeric antigen receptors (CAR-T cells) has changed the therapeutic landscape of hematological malignancies, particularly for acute lymphoblastic leukemia and large B cell lymphoma, where two different CAR-
Autor:
Reuben Benjamin, Charlotte Graham, Deborah Yallop, Agnieszka Jozwik, Oana C Mirci-Danicar, Giovanna Lucchini, Danielle Pinner, Nitin Jain, Hagop Kantarjian, Nicolas Boissel, Marcela V Maus, Matthew J Frigault, André Baruchel, Mohamad Mohty, Athos Gianella-Borradori, Florence Binlich, Svetlana Balandraud, Fabien Vitry, Elisabeth Thomas, Anne Philippe, Sylvain Fouliard, Sandra Dupouy, Ibtissam Marchiq, Maria Almena-Carrasco, Nicolas Ferry, Sylvain Arnould, Cyril Konto, Paul Veys, Waseem Qasim, Antonio Pagliuca, Ghulam Mufti, Piers Patten, Shireen Kassam, Stephen Devereux, Majid Kazmi, Kirsty Cuthill, Victoria Potter, Andrea Kuhnl, Victoria Metaxa, Laarni Bonganay, Orla Stewart, Rose Ellard, Lorraine Catt, Jen Lewis, Farzin Farzaneh, Jackie Chappell, Alice Mason, Vicky Chu, Alan Dunlop, Adeel Saleem, Gary Cheung, Helena Munro, Elka Giemza, Oana Ciocarlie, Jan Chu, Persis Amrolia, Kanchan Rao, Robert Chiesa, Juliana Silva, Annette Hill, Maria Finch, Lindsey Young, Harvinder Hara, Sujith Samarasinghe, Anupama Rao, Ajay Vora, Kimberley Gilmour, Christine Rivat, Clare Murphy, Gulrukh Ahsan, Rasha Said Shamsah, Jesmina James, Sarah Inglott, Gary Wright, Stuart Adams, Natalia Izotova, Marina Konopleva, William Wierda, Elias Jabbour, Partow Kebrieai, Emily Jones, Kara McGee, Marcela Maus, Matthew Frigault, Jami Brown, Vesselina Toncheva, Keagan Casey, Hanno Hock, Meaghan A McKeown, Richard Mathews, Thomas Spitzer, Emmanuel Raffoux, Etienne Lengliné, Raphael Itzykson, Florence Rabian, Jérôme Larghero, Isabelle Madelaine, Elie Azoulay, Emmanuelle Clappier, Sophie Caillat-Zucman, Martine Meunier, Karine Celli-Lebras, Marie-Thérèse Tremorin, Karima Yakouben, Françoise Mechinaud-Heloury, Audrey Grain, Aurélia Alimi, Julie Roupret, Delphine Chaillou, Hélène Cavé, Aurelie Caye-Eude, Odile Fenneteau, Elodie Lainey, Jerome Naudin, Eolia Brissot, Remy Dulery, Florent Malard, Clémence Mediavilla, Agnès Bonnin, Anne Vekhoff, Tounes Ledraa, Anne Daguenel-Nguyen
Publikováno v:
The Lancet. 396:1885-1894
Summary Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broadening access and applicability. UCART19 is
Autor:
Marcela V. Maus, Matthew J. Frigault
Publikováno v:
J Clin Invest
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell ma
Autor:
Jamie E. DeNizio, Yan Wang, Simon F. Lacey, Vijay Bhoj, Tyler J. Reich, In-Young Jung, Regina M. Young, David L. Porter, John Scholler, Minnal Gupta, Julie K. Jadlowsky, Carl H. June, Todd Yoder, Christopher J. Ott, Megan M. Davis, Kathleen M. Haines, Irina Kulikovskaya, Golnaz Vahedi, Katherine T. Marcucci, Weimin Kong, Jun Xu, J. Joseph Melenhorst, John K. Everett, Joseph A. Fraietta, Marcela V. Maus, Erik F. Williams, Bruce L. Levine, Wenliang Wang, James E. Bradner, Rahul M. Kohli, Alexander Dimitri, Frederic D. Bushman, Maria Fasolino
Publikováno v:
J Clin Invest
Chimeric antigen receptor (CAR) T cells have induced remarkable antitumor responses in B cell malignancies. Some patients do not respond because of T cell deficiencies that hamper the expansion, persistence, and effector function of these cells. We u
Autor:
Lyh Ping Lam, Sundar Jagannath, Michaela Liedtke, M. Travis Quigley, Jacalyn Rosenblatt, Richard A. Morgan, Fabio Petrocca, Greg Russotti, Monica Massaro, Kevin G. Friedman, Noopur Raje, Kristen Hege, David S. Siegel, James N. Kochenderfer, Deepu Madduri, Jesus G. Berdeja, Yi Lin, Zhihong Yang, Julie Wang, Nikhil C. Munshi, Marcela V. Maus, Ashley Turka, Timothy B. Campbell
Publikováno v:
N Engl J Med
BACKGROUND: Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS: In this phase 1 study involving patient
Autor:
Marcela V. Maus
Publikováno v:
The Lancet. 398:466-467
Autor:
Daniel E Grinshpun, Mikolaj Slabicki, Taeyoon Kyung, Quinlan L. Sievers, Michael Kann, Rebecca C. Larson, Amanda Walker, Max Jan, Alexander Tepper, Andrea Schmidts, Benjamin L. Ebert, Maria L. Cabral, Marcela V. Maus, Michael E. Birnbaum, Jessica A. Gasser, Amanda A. Bouffard, Andrew A Guirguis, Irene Scarfò, Ana P. Castano, Adam S. Sperling
Publikováno v:
Sci Transl Med
PMC
PMC
Cell-based therapies are emerging as effective agents against cancer and other diseases. As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen receptor (CAR) T cells effectively target hematologic malignancies but c